Insider trade

Merck (MRK): Director received 126.46 units

Surendralal Lanca Karsanbhai, Director at Merck, reported a grant / award of 126.46 units.

126.46
Derivative units · @ $128.50
Traded
Jun 30, 2026
Filed
Jul 1, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  2. May 4, 2026Federal contract · $43K obligatedDepartment of Veterans Affairs awarded Merck: $43K obligated to date
  3. May 8, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  4. May 11, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  5. May 11, 2026Federal contract · $342K obligatedDepartment of Veterans Affairs awarded Merck: $342K obligated to date
  6. May 21, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  7. Jun 12, 2026FDAFDA drug approval: Welireg
  8. Jun 12, 2026FDAFDA drug approval: Keytruda
  9. Jun 12, 2026FDAFDA drug approval: Keytruda Qlex
  10. Jun 12, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  11. Jun 12, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  12. Jun 23, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  13. Jun 24, 2026FDAFDA drug approval: Keytruda
  14. Jun 24, 2026FDAFDA drug approval: Keytruda Qlex

What came next

  1. Jul 10, 2026FDAFDA drug approval: Keytruda
  2. Jul 10, 2026FDAFDA drug approval: Keytruda Qlex
  3. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
  4. Aug 5, 2026Insider · 2 peopleInsiders: 6 sales (~$9.2M)
  5. Aug 6, 2026Insider · 2 peopleInsiders: 4 sales (~$2.8M)
  6. Aug 10, 2026InsiderOfficer sold ~$2.71M of MRK shares in the open market
  7. Aug 11, 2026Insider · 1 personInsiders: 2 sales (~$1.7M)
  8. Aug 12, 2026Insider · 2 peopleInsiders: 3 sales (~$12.3M)
  9. Aug 13, 2026InsiderOfficer sold ~$1.35M of MRK shares in the open market
  10. Aug 19, 2026Congress · 1 personMembers of Congress: 2 purchases
  11. Sep 14, 2026Federal contract · $1.6M obligatedDepartment of Health and Human Services awarded Merck: $1.63M obligated to date
  12. Sep 21, 2026FDAFDA drug approval: Winrevair
  13. Sep 24, 2026FDAFDA drug approval: Welireg
  14. Sep 24, 2026Federal contract · $21K obligatedDepartment of Veterans Affairs awarded Merck: $21K obligated to date
  15. Sep 24, 2026CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  16. Oct 9, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“(d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026.”
  17. Oct 14, 2026FDAFDA drug approval: Enflonsia
  18. Oct 16, 2026FDAFDA drug approval: Keytruda
  19. Oct 16, 2026FDAFDA drug approval: Keytruda Qlex
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Merck

For Merck, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 3 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by Surendralal Lanca Karsanbhai, Director

The full history of Surendralal Lanca Karsanbhai, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Merck (MRK) insider traded, and how much?

Surendralal Lanca Karsanbhai, Director at Merck, reported a grant / award of 126.46 units. At $128.50.

When did it happen, and when was it made public?

Traded: Jun 30, 2026. Filed: Jul 1, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Merck recently?

For Merck, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 3 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days. They are listed on the MRK page.

Does this mean MRK stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data